[논문]Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Ko, Yoon Ho; Lee, Myung Ah; Hong, Yeong Seon; Lee, Kyung Shik; Park, Hyun Jin; Yoo, Ie Ryung; Kim, Yeon Sil; Kim, Young Kyoon; Jo, Keon Hyun; Wang, Young Pil; Lee, Kyo Young; Kang, Jin Hyoung

doi:10.3904/kjim.2007.22.3.178

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients 원문보기

The Korean journal of internal medicine : KJIM, v.22 no.3, 2007년, pp.178 - 185

Ko, Yoon Ho (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.) , Lee, Myung Ah (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.) , Hong, Yeong Seon (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.) , Lee, Kyung Shik (Lung Cancer Multidisciplinary Team of Kangnam St. Mary's Hospital, Division of Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.) , Park, Hyun Jin (Department of Radiology, The Catholic University of Korea, Seoul, Korea.) , Yoo, Ie Ryung (Department of Nuclear Medicine, The Catholic University of Korea, Seoul, Korea.) , Kim, Yeon Sil (Department of Radiation Oncology, The Catholic University of Korea, Seoul, Korea.) , Kim, Young Kyoon (Division of Pulmonology, Department of Internal Medicine, The Catholic) , Jo, Keon Hyun , Wang, Young Pil , Lee, Kyo Young , Kang, Jin Hyoung

Abstract ▼ AI-Helper

BackgroundSecond-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting.MethodsDocetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed.ResultsFrom October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9~4.0) and 2.8 months (95% confidence interval: 1.0~4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths.ConclusionsA docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting.

주제어

참고문헌 (23)

1 Non Small Cell Lung Cancer Collaborative Group Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 1995 311 899 909 7580546
2 Shepherd FA Dancey J Ramlau R Mattson K Gralla R O'Rourke M Levitan N Gressot L Vincent M Brukes R Coughlin S Kim Y Berille J Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 2000 18 2095 2103 10811675

상세보기
3 Fossella FV DeVore R Kerr RN Crawford J Natale RR Dunphy F Miller V Lee JS Moore M Gandara D Karp D Vokes E Kris M Kim Y Gamza F Hammershaimb L The TAX 320 Non-Small Cell Lung Cancer Study Group Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens J Clin Oncol 2000 18 2354 2362 10856094

상세보기
4 Hanna N Shepherd FA Fossella FV Pereira JR De Marinis F von Pawel J Gatzemeier U Tsao TC Pless M Muller T Lim HL Desch C Szondy K Geravis R Sharharyar Manegold C Paul S Paoletti P Einhorn L Bunn PA Jr Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 2004 22 1589 1597 15117980

상세보기
5 Fossella FV Lee JS Shin DM Calayag M Huber M Perez-Soler R Murphy WK Lippman S Benner S Glisson B Phase II study of docetaxel for advanced or metastatic platinum refractory non-small-cell lung cancer J Clin Oncol 1995 13 645 651 7884425

상세보기
6 Gandara DR Vokes E Green M Bonomi P Devore R Comis R Carbone D Karp D Belani C Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial J Clin Oncol 2000 18 131 135 10623703

상세보기
7 Gridelli C Perrone F Monfardini S Lung cancer in the elderly Eur J Cancer 1997 33 2313 2314 9616273

상세보기
8 Inoue A Usui K Ishimoto O Matsubara N Tanaka M Kanbe M Gomi K Koinumaru S Saijo Y Nukiwa T A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer Lung Cancer 2006 52 83 87 16483687
9 Esteban E Gonzalez de Sande L Fernandez Y Corral N Fra J Muniz I Vieitez JM Palcio I Fernandez JL Estrada E Lacave AJ Prospective randomized phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum based chemotherapy Ann Oncol 2003 14 1640 1647 14581272
10 Gervais R Ducolone A Breton JL Braun D Lebeau B Vaylet F Debieuvre D Pujol JL Tredaniel J Coulet P Quoix E Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second line therapy in patients with advanced non small cell lung cancer (NSCLC) Ann Oncol 2005 16 90 96 15598944
11 Gridelli C Gallo C Di Maio M Barletta E Illiano A Maione P Salvagni S Poantedosi FV Palazzolo G Caffo O Ceribelli A Falcone A Mazzanti P Brancaccio L Capuano MA Isa L Babera S Perrone F A randomized clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second line treatment of non-small-cell lung cancer Br J Cancer 2004 91 1996 2004 15558071
12 Schuette W Nagel S Blankenburg T Lautenschlaeger C Hans K Schmidt EW Dittrich I Schweisfurth H von Weikersthal LF Raghavachar A Reissig A Serke M Phase III study of second line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3 weekly docetaxel J Clin Oncol 2005 23 8389 8395 16293869

상세보기
13 Camps C Massuti B Jimenez A Maestu I Gomez RG Isla D Gonzalez JL Amenar D Blasco A Rosell R Carrato A Vinolas N Batista N Giron CG Galan A Lopez M Blanco R Provencio M Diz P Felip E Randomized phase III study of 3 weekly versus weekly docetaxel in pretreated advanced non small cell lung cancer Ann Oncol 2006 17 467 472 16371411
14 Barlesi F Jacot W Astoul P Pujol JL Second line treatment for advanced non-small cell lung cancer: a systematic review Lung Cancer 2006 51 159 172 16360238
15 Gridelli C Perrone F Gallo C Rossi A Barletta E Barzelloni ML Creazzola S Gatani T Fiore F Guida C Scognamiglio F Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial Anticancer Res 1999 19 4535 4538 10650806

상세보기
16 Shim BY Jim CH Song SH Ahn MI Hong EJ Kim SW Kim S Jo MS Cho DG Cho KD Yoo J Kim HK The safety and efficacy of second-line single docetaxel (75 mg/m 2 ) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum based chemotherapy Cancer Res Treat 2005 37 339 343 19956369

상세보기
17 Baker SD Zhao M Lee CK Verweij J Zabelina Y Brahmer JR Wolff AC Sparreboom A Carduci MA Comparative pharmacokinetics of weekly and every-three-weeks docetaxel Clin Cancer Res 2004 10 1976 1983 15041715

상세보기
18 Bruno R Hille D Riva A Vivier N ten Bokkel Huinnink WW van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 1998 16 187 196 9440742

상세보기
19 Sweeney CJ Miller KD Sissons SE Nozaki S Heilman DK Shen J Sledge GW Jr The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 2001 61 3369 3372 11309294
20 Giannakakou P Robey R Fojo T Blagosklonny MV Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity Oncogene 2001 20 3806 3813 11439344

상세보기
21 Sparreboom A Zhao M Brahmer JR Verweij J Baker SD Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 2002 773 183 190

상세보기
22 Loos WJ Baker SD Verweij J Boonstra JG Sparreboom A Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins Clin Pharmacol Ther 2003 74 364 371 14534523

상세보기
23 Seidman AD Berry D Cirrincione C Harris L Dressler L Muss H Naughton M Norton L Winer E Hudis C CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1 hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC Proc Am Soc Clin Oncol 2004 22 6s (suppl 14; abstr 512)

LOADING...

원문 URL 링크

DOI : 10.3904/kjim.2007.22.3.178
한국학술정보 : 저널
PubMed Central : 저널 > 논문 [무료]
대한내과학회 : 저널
ScienceCentral : 저널
Korea Open Access Journals : 저널
AccessON : 저널

*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

저작권 관리 안내

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관

저장형식

Text(ASCII format)
Excel format
RefWorks Direct Export
RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

연합인증